RT Journal Article
SR Electronic
T1 Using early data to estimate the actual infection fatality ratio from COVID-19 in France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.22.20040915
DO 10.1101/2020.03.22.20040915
A1 Lionel Roques
A1 Etienne Klein
A1 Julien Papaïx
A1 Antoine Sar
A1 Samuel Soubeyrand
YR 2020
UL http://medrxiv.org/content/early/2020/05/07/2020.03.22.20040915.abstract
AB The number of screening tests carried out in France and the methodology used to target the patients tested do not allow for a direct computation of the actual number of cases and the infection fatality ratio (IFR). The main objective of this work is to estimate the actual number of people infected with COVID-19 and to deduce the IFR during the observation window in France. We develop a ‘mechanistic-statistical’ approach coupling a SIR epidemiological model describing the unobserved epidemiological dynamics, a probabilistic model describing the data acquisition process and a statistical inference method. The actual number of infected cases in France is probably higher than the observations: we find here a factor ×8 (95%-CI: 5–12) which leads to an IFR in France of 0.5% (95%-CI: 0.3 – 0.8) based on hospital death counting data. Adjusting for the number of deaths in nursing homes, we obtain an IFR of 0.8% (95%-CI: 0.45 – 1.25). This IFR is consistent with previous findings in China (0.66%) and in the UK (0.9%) and lower than the value previously computed on the Diamond Princess cruise ship data (1.3%).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by INRAEAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the data in this manuscript are available from public sources: Johns Hopkins University Center for Systems Science and Engineering, Santé publique France, and Korean Center for Disease Control https://github.com/CSSEGISandData/COVID-19